Dynamic monitoring of HbA1c in Russian regions: data comparison of mobile medical center (Diamodul) and national diabetes register of Russian Federation

BACKGROUND: Glikogemoglobin (HbA_1c) is a key clinical marker for evaluating the effectiveness of glucose-lowering therapy for patients with diabetes mellitus (DM) and the quality of diabetic care.

AIMS: to conduct dynamic monitoring of the quality of glycemic control in DM patients based on a comprehensive examination in mobile medical center (Diamodul) during repeated visits to the regions in 2019 compared with visits of Based Federal program “Diabetes Mellitus” (2005–2010) and data of the National diabetes register (NDR).

MATERIALS AND METHODS: The object of the study: patients with T1DM and T2DM examined in Diamodul in 2019 in Voronezh region (Vr), Krasnodar region (Kr) (n = 600), there were “dynamic” group of re-examined (Vr n = 224; Kr n = 113), “random” group of new patients (Vr n = 72; Kr n = 191); group of adult patients from NDR with indicated HbA_1c in 2019 (n = 2410067).

RESULTS: According to Diamodul, the HbA_1c levels are significantly worse than they were reported to NDR: the proportion of patients achieved HbA_1c <7% for T1DM is 13.3% and 11.7%; T2DM – 25.1% and 28.6%, in Kr and Vr, respectively; in NDR: T1DM – 37.4%, T2DM – 52.2%. The average HbA_1c values in the Diamodul are higher than in NDR by 0.95% for T1DM, 1.41% for T2DM patients. The proportion of patients with HbA_1c≥9% decrease in dynamic of examinations through years in T1: in Vr from 53.1% in 2005 and 55.8% in 2010 to 42.9% in 2019, in Kr from 53.2% in 2006 to 43.8% in 2019; also there were decreases in the average HbA_1c values in Vr from 9.3% in 2005 and 9.4% in 2010 to 8.8% in 2019; in Kr from 9.1% in 2006 to 8.7% in 2019. In T2DM patients with the best parameters of DM control in a whole, the positive trends were less pronounced and are assessed as non-deterioration: the proportion of HbA_1c≥9 % in Vr: 34.7%–34.7%–36.4%, in Kr 40.1%–28.4%; average values of HbA_1c: 8.2%–8.4%–8.5% and 8.6%–8.4%, respectively.

CONCLUSIONS: The data of the research clearly indicates the need for 100% inclusion of HbA_1c in the examination standards in all DM patients at the primary level at least 1 time per year, in order to monitor the real clinical situation, the effectiveness of glucose-lowering therapy and its timely intensification to prevent development of complications.

diabetes mellitus, mobile medical center, Diamodule, glikogemoglobin (A1c), the register of diabetes mellitus

1. IDF Diabetes Atlas, 9th edition. Brussels: International Diabetes Federation; 2019. Available from: https://www.diabetesatlas.org/en/

2. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Атлас регистра сахарного диабета Российской Федерации. Статус 2018 г. // Сахарный диабет. — 2019. — Т. 22. — №S2-2. — C. 4–61. [Dedov II, Shestakova MV, Vikulova OK, et al. Atlas of Diabetes Register in Russian Federation, status 2018. Diabetes mellitus. 2019;22(S2-2):4–61. (In Russ.)] doi: https://doi.org/10.14341/DM12208

3. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией Дедова И.И., Шестаковой М.В., Майорова А.Ю. 9-й вып. // Сахарный диабет. — 2019. — Т. 22. — №S1-1. — C. 1–144. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(S1-1):1–144. (In Russ.)] doi: https://doi.org/10.14341/DM221S1

4. Дедов И.И., Шестакова М.В., Сунцов Ю.И., и др. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007–2012 годы» // Сахарный диабет. — 2013. — №2S. — C. 2–48. [Dedov II, Shestakova MV, Suntsov YI, et al. Federal targeted programme ‘Prevention and Management of Socially Significant Diseases (2007−2012)’: results of the ‘Diabetes mellitus’ sub-programme. Diabetes mellitus. 2013;(2S):2–48. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-3879

5. Дедов И.И., Сунцов Ю.И., Болотская Л.Л., и др. Скрининг осложнений сахарного диабета как метод оценки лечебно-профилактической помощи больным // Сахарный диабет. — 2006. — №4. — C. 38–42. [Dedov II, Suntsov YI, Bolotskaya LL, et al. Skrining oslozhneniy sakharnogo diabetakak metod otsenki lechebno-profilakticheskoypomoshchi bol’nym. Diabetes mellitus. 2006;(4):38–42. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-6188

6. Викулова О.К. «Диамобиль» — масштабный профилактический проект // Медицина: целевые проекты. — 2019. — №33. — С. 47−48. [Vikulova OK. «Diamobil’» — masshtabnyi profilakticheskii proekt. Meditsina: tselevye proekty. 2019;(33):47–48. (In Russ.)]

7. ACCORD study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: https://doi.org/10.1056/NEJMoa0802743

8. The ADVANCE collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: https://doi.org/10.1056/NEJMoa0802987

9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998;352(9131):837–853. doi: https://doi.org/10.1016/S0140-6736(98)07019-6

10. National Diabetes Audit, 2015−2016: Report 1, Care Processes and Treatment Targets [cited 2017 January 31]. Available from: https://webarchive.nationalarchives.gov.uk/20180328131154/http://digital.nhs.uk/media/30447/National-Diabetes-Audit-2015-2016-Report-1-Care-Processes-and-Treatment-Targets-/Any/nati-diab-rep1-audi-2015-16

11. Kazemian P, Shebl FM, McCann N, et al. Evaluation of the Cascade of Diabetes Care in the United States, 2005−2016. JAMA Internal Medicine. 2019. doi: https://doi.org/10.1001/jamainternmed.2019.2396

12. Мисникова И.В., Древаль А.В., Ковалева Ю.А. Гликированный гемоглобин — основной параметр в контроле сахарного диабета // Сахарный диабет. — 2008. — №4. — C. 38–40. [Misnikova IV, Dreval’ AV, Kovaleva YA. Glikirovannyy gemoglobin – osnovnoy parametr v kontrole sakharnogo diabeta. Diabetes mellitus. 2008;(4):38–40. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-5588

13. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития // Сахарный диабет. — 2015. — T. 18. — №3. — С. 5–22. [Dedov II, Shestakova MV, Vikulova OK. National register of diabetes mellitus in Russian Federation: status on 2014. Diabetes mellitus. 2015;18(3):5–22. (In Russ.)] doi: https://doi.org/10.14341/DM201535-22

14. Шестакова М.В., Викулова О.К., Железнякова А.В., и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? // Терапевтический архив. — 2019. — Т. 91. — №10. — С. 4–13. [Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: what has changed over the decade? 2019;91(10):4–13. (In Russ.)] doi: https://doi.org/10.26442/00403660.2019.10.000364

15. Ильин А.В., Арбузова М.И., Князева А.П. Гликированный гемоглобин как ключевой параметр при мониторинге больных сахарным диабетом. Оптимальная организация исследований // Сахарный диабет. — 2008. — №2. — C. 60–64. [Il’in AV, Arbuzova MI, Knyazeva AP. Glikirovannyy gemoglobin kak klyuchevoy parametr pri monitoringe bol’nykh sakharnym diabetom. Optimal’naya organizatsiya issledovaniy. Diabetes mellitus. 2008(2):60–64. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-5762